GlassScriptPhysician profile
Mariam Bakhtary
NPI 1134492895
$4,902.56
in general payments reported to CMS, 2019-2025
18 companies · $66.00 in 2025
The $66.00 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $454 · 2021: $1,418 · 2022: $921 · 2023: $306 · 2024: $215 · 2025: $66.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560 · Education: $27.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.75 |
| Education | $27.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,171.52 | 2019-2024 | Veklury |
| Cipla USA INC. | $786.69 | 2019-2021 | |
| Viiv Healthcare Company | $721.12 | 2019-2024 | Dovato |
| Allergan, INC. | $440.64 | 2019 | |
| Insmed, INC. | $410.40 | 2019-2022 | |
| Janssen Biotech, INC. | $272.37 | 2019-2022 | |
| Shionogi INC | $239.70 | 2021-2024 | Fetroja |
| Janssen Products, LP | $224.00 | 2019 | |
| Merck Sharp & Dohme LLC | $191.33 | 2019-2021 | |
| Abbvie INC. | $177.32 | 2021-2025 | Teflaro, Dalvance, Avycaz |
| Melinta Therapeutics, LLC | $102.36 | 2019-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $32.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| La Jolla Pharmaceutical Company | $26.51 | 2025 | Xacduro |
| Philips North America LLC | $22.87 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $19.27 | 2022 | |
| Nabriva Therapeutics, Plc | $19.04 | 2021 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Bakhtary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.